Neuromodulation for Accidental Bowel Leakage
Status: | Recruiting |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/27/2018 |
Start Date: | February 9, 2018 |
End Date: | October 2020 |
Contact: | Halina M Zyczynski, MD |
Email: | hzyczynski@mail.magee.edu |
Phone: | (412) 641-1440 |
This study is a multi-center, randomized clinical trial of women with refractory accidental
bowel leakage (ABL) symptoms who have failed to achieve satisfactory symptom control from 2
first-line treatments for ABL: supervised pelvic muscle training (PMT) and constipating
medication. The purpose of this study is to compare percutaneous tibial nerve stimulation
(PTNS) to a validated sham to determine if PTNS is effective for the treatment of fecal
incontinence (FI) in women.
The investigators will test the null hypothesis that change from baseline in St. Mark's
(Vaizey) score after 12 weeks of stimulation is not significantly different in women with
symptomatic ABL receiving PTNS treatments compared to women receiving sham PTNS treatments.
bowel leakage (ABL) symptoms who have failed to achieve satisfactory symptom control from 2
first-line treatments for ABL: supervised pelvic muscle training (PMT) and constipating
medication. The purpose of this study is to compare percutaneous tibial nerve stimulation
(PTNS) to a validated sham to determine if PTNS is effective for the treatment of fecal
incontinence (FI) in women.
The investigators will test the null hypothesis that change from baseline in St. Mark's
(Vaizey) score after 12 weeks of stimulation is not significantly different in women with
symptomatic ABL receiving PTNS treatments compared to women receiving sham PTNS treatments.
The overarching goal of this randomized clinical trial is to determine if PTNS is more
effective than sham PTNS for the treatment of FI in women after 12 weeks of treatment and 1
year after initiating treatment. This is a two-part trial with a Run-In Phase prior to
randomization. The trial has the following primary aim:
To determine whether the change from baseline in St. Mark's (Vaizey) score in women with
symptomatic ABL undergoing PTNS differs from sham after 12 weeks of stimulation.
Additional secondary aims include:
1. To compare changes from baseline in self-reported functional outcomes after 12 weekly
stimulation sessions in both PTNS and sham groups in Part 1.
2. To determine whether symptom relief amongst study "responders" can be sustained for one
year with maintenance treatments in Part II.
3. To determine the impact of completing a bowel diary and receiving education on FI on
symptom severity.
4. To determine the ability of the PFDN ABL phone app bowel diary to detect changes from
baseline in fecal incontinence episodes recorded to after 12 weeks of stimulation
sessions.
effective than sham PTNS for the treatment of FI in women after 12 weeks of treatment and 1
year after initiating treatment. This is a two-part trial with a Run-In Phase prior to
randomization. The trial has the following primary aim:
To determine whether the change from baseline in St. Mark's (Vaizey) score in women with
symptomatic ABL undergoing PTNS differs from sham after 12 weeks of stimulation.
Additional secondary aims include:
1. To compare changes from baseline in self-reported functional outcomes after 12 weekly
stimulation sessions in both PTNS and sham groups in Part 1.
2. To determine whether symptom relief amongst study "responders" can be sustained for one
year with maintenance treatments in Part II.
3. To determine the impact of completing a bowel diary and receiving education on FI on
symptom severity.
4. To determine the ability of the PFDN ABL phone app bowel diary to detect changes from
baseline in fecal incontinence episodes recorded to after 12 weeks of stimulation
sessions.
Inclusion Criteria:
- Women ≥ 18 years of age
- FI symptoms ≥ 3 months
- Baseline St. Mark's score of ≥ 12
- Attended ≥ 2 supervised PMT for ABL
- Intolerance, unwillingness, or inadequate response to constipating medications
- Current negative colon cancer screening based on the USPSTF's recommendation for
colorectal cancer screening (2016)
Exclusion Criteria:
- Previous PTNS treatment
- History of uncontrolled diarrhea in the past 3 months (usual or most common stool type
over the preceding 3 months of 7 on the Bristol Stool Form Scale)
- History of severe constipation in the past 3 months (1 on the Bristol Stool Form
Scale)
- History of inflammatory bowel disease (includes Crohn's disease and ulcerative
colitis, but does not include irritable bowel disease)
- Unrepaired rectovaginal fistula/chronic 4th degree laceration
- Full thickness rectal prolapse
- History of congenital anorectal malformation
- History of bowel resection surgery for any indication
- Minor anal procedures within 6 months for treatment of ABL (injection of bulking agent
or radiofrequency energy) or ligation of hemorrhoids
- Prior pelvic or abdominal radiation
- Diagnosis of cancer of the descending colon or anus
- Diagnosis of cancer in the region where the PTNS or sham needles or surface electrodes
would be placed
- Pacemaker, implantable defibrillator
- Current use of Interstim sacral nerve stimulator or TENS in the pelvic region, back,
or legs
- Clinically significant neurological disorders known to affect anal continence
- Coagulopathy
- Severe peripheral edema preventing accurate placement of PTNS needles
- Chronic swollen, infected, inflamed skin or skin eruptions (e.g., phlebitis,
thrombophlebitis, varicose veins) in the region where the PTNS or sham needles or
surface electrodes would be placed
- Metal implant in foot/toes near TENS electrode location
- Marked sensory deficit (numbness) of feet or ankles in the region where the PTNS or
sham needles or surface electrodes would be placed
- Childbirth within the last 3 months
- Pregnant or planning to become pregnant during the study duration 1 year; a urine
pregnancy test will be performed and must be negative by the first intervention visit
if the participant is of childbearing potential
- Unwilling to use acceptable form of contraceptive if the participant is of
childbearing potential
- Participation in another intervention trial impacting bowel function
- Inability to provide informed consent, complete questionnaires independently, or to
attend intervention sessions
- Unable or unwilling to complete the bowel diary in Run-In Phase (valid diary defined
as data from ≥ 10 of 14 days with minimum of 3 consecutive days per week)
- Unwilling to download bowel diary app onto smartphone if the participant owns a
smartphone
- Visual impairment prohibiting reading the paper diary, the smart phone screen
- Unable to speak, read, or write in English or Spanish at a basic level
We found this trial at
9
sites
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Holly E Richter, PhD, MD
Phone: 205-934-7874
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: David Rahn, MD
Phone: 214-645-3848
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
Downey, California 90242
Principal Investigator: John N Nguyen, MD
Phone: 562-657-2642
Click here to add this to my saved trials
Durham, North Carolina 27707
Principal Investigator: Anthony G Visco, MD
Phone: 919-401-1018
Click here to add this to my saved trials
La Jolla, California 92037
Principal Investigator: Emily Lukacz, MD
Phone: 858-657-8435
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Lily Arya, MD, MS
Phone: 215-615-6569
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Principal Investigator: Halina M Zyczynski, MD
Phone: 412-641-1440
Click here to add this to my saved trials
Providence, Rhode Island 02903
Principal Investigator: Vivian Sung, MD
Phone: 401-453-7560
Click here to add this to my saved trials
San Diego, California 92120
Principal Investigator: Shawn A Menefee, MD
Phone: 619-221-6200
Click here to add this to my saved trials